Showing results (91-100 of 140) with videos related to
Sort By:
Pageof 14
Scientific Reports|August 31, 2019
Phenotypic switching in Candida tropicalis alters host-pathogen interactions in a Galleria mellonella infection modelHugo F Perini, Alane T P Moralez, Ricardo S C Almeida, et al.Practical Radiation Oncology|July 12, 2014
Clinical utility of integrated positron emission tomography/computed tomography imaging in the clinical management and radiation treatment planning of locally advanced rectal cancerJonathan T Whaley, Annemarie T Fernandes, Robert Sackmann, et al.Microbial Pathogenesis|June 3, 2023
Altered phagocytosis and morphogenesis of phenotypic switching-derived strains of the pathogenic Candida tropicalis co-cultured with phagocytic cellsEloiza A Paulo, Cassia M de Souza, Hugo F Perini, et al.Journal of Visualized Experiments : Jove|August 7, 2010
Deficient Pms2, ERCC1, Ku86, CcOI in field defects during progression to colon cancerHuy Nguyen, Cristy Loustaunau, Alexander Facista, et al.Current Medical Research and Opinion|July 23, 2020
Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinomaArielle G Bensimon, Yichen Zhong, Umang Swami, et al.Journal of Clinical Pharmacology|May 16, 2024
Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and LabelingDhananjay D Marathe, Petra M Jauslin, Huub Jan Kleijn, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 21, 2017
Challenges and opportunities in primary CNS lymphoma: A systematic reviewMariana N Kerbauy, Fabio Y Moraes, Benjamin H Lok, et al.The Journal of Biological Chemistry|November 23, 2000
A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Sträussler-Scheinker disease A117VF Tagliavini, P M Lievens, C Tranchant, et al.European Journal of Cancer (Oxford, England : 1990)|November 26, 2023
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohortEric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, et al.The Lancet. Oncology|April 14, 2025
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 studyRamaprasad Srinivasan, Othon Iliopoulos, Kathryn E Beckermann, et al.Pageof 14